MI&T Congressi
MI&T Srl has consolidated over ten years of proven experience in the organization of congresses, conferences and medical-scientific courses and in the provision of specific services for medical-scientific associations, in Italy and abroad.
3rd International Summit on Lung Cancer
MI&T Congressi
How to Select EGFR-Mutated Patients for EGFR+CT Combo in NSCLC
FEATURING
Pasi Janne
- 4 views
- July 26, 2024
MI&T Congressi
ADC in Combination With Immunotherapy for NSCLC
FEATURING
Stephen Liu
- 108 views
- July 26, 2024
MI&T Congressi
IO Long-Term Survival in Advanced NSCLC
FEATURING
Rolf A. Stahel
- 24 views
- July 25, 2024
MI&T Congressi
Selecting Patients for CTLA4 Therapy for NSCLC
FEATURING
Rafal Dziadziuszko
- 19 views
- July 25, 2024
MI&T Congressi
New Immune Checkpoint Inhibitors in Lung Cancer
FEATURING
Solange Peters
- 25 views
- July 25, 2024
MI&T Congressi
How the Experts Treat: Neoadjuvant Immunotherapy for Resected NSCLC
FEATURING
Mariano Provencio Pulla
- 16 views
- July 24, 2024
MI&T Congressi
How the Experts Treat: Adjuvant or Neoadjuvant Immunotherapy for NSCLC
FEATURING
Tina Cascone
- 32 views
- July 24, 2024
MI&T Congressi
N2 Disease in NSCLC: Who Is Resectable?
FEATURING
Mariana Brandão
- 17 views
- July 24, 2024
MI&T Congressi
Maintenance IO in Stage III Unresectable NSCLC
FEATURING
Anne-Marie Dingemans
- 14 views
- July 22, 2024
MI&T Congressi
Neoadjuvant and Adjuvant Therapies in NSCLC: Are We Saving Lives?
FEATURING
Giorgio Scagliotti
- 44 views
- July 22, 2024
MI&T Congressi
MET Exon 14 Skipping Mutations in NSCLC
FEATURING
Oliver Gautschi
- 41 views
- July 19, 2024
MI&T Congressi
Current and Future Options for Relapsed SCLC
FEATURING
Luis Paz-Ares
- 79 views
- July 18, 2024
MI&T Congressi
Immunotherapy for Patients With Mesothelioma
FEATURING
Joachim Aerts
- 23 views
- July 18, 2024
MI&T Congressi
How the Experts Treat: Adjuvant Immunotherapy for Resected NSCLC
FEATURING
Dolores Isla
- 30 views
- July 18, 2024
MI&T Congressi
Perspectives for NSCLC Patients Not Obtaining Complete Pathological Response
FEATURING
Tony Mok
- 26 views
- July 18, 2024
MI&T Congressi
Options for BRAF-Mutated NSCLC Patients
FEATURING
David Planchard
- 9 views
- July 16, 2024
MI&T Congressi
Preventing Lung Cancer: Hope or Reality?
FEATURING
Ugo Pastorino
- 32 views
- July 12, 2024
MI&T Congressi
How the Experts Treat: Neoadjuvant or Adjuvant Targeted Therapy in Resectable Oncogene-Addicted NSCLC
FEATURING
Jarushka Naidoo
- 125 views
- July 12, 2024
MI&T Congressi
Surgery at the Time of Immunotherapy for Early Stage NSCLC
FEATURING
Jonathan Spicer
- 18 views
- July 12, 2024
MI&T Congressi
Radiotherapy for N2 Resected NSCLC
FEATURING
Cécile Le Péchoux
- 10 views
- July 12, 2024